2. Search Result
Search Result
Results for "

(YTH) domain-containing family proteins (YTHDF)

" in MedChemExpress (MCE) Product Catalog:

1323

Inhibitors & Agonists

16

Screening Libraries

14

Fluorescent Dyes

30

Biochemical Assay Reagents

110

Peptides

1

MCE Kits

24

Inhibitory Antibodies

176

Natural
Products

677

Recombinant Proteins

40

Isotope-Labeled Compounds

540

Antibodies

5

Click Chemistry

158

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13271A
    Tubastatin A
    35+ Cited Publications

    		 Beta-lactamase HDAC Autophagy Apoptosis Cancer
    Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubastatin A
  • HY-N6684
    Deoxynivalenol
    15+ Cited Publications

    Vomitoxin

    		 P-glycoprotein Metabolic Disease
    Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .
    Deoxynivalenol
  • HY-119254
    BAY-850
    5 Publications Verification

    		 Epigenetic Reader Domain Metabolic Disease
    BAY-850, a chemical probe, is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC50 of 166 nM .
    BAY-850
  • HY-13428
    Tubacin
    20+ Cited Publications

    		 Beta-lactamase HDAC Virus Protease Cancer
    Tubacin is a potent and selective inhibitor of HDAC6, with an IC50 value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubacin
  • HY-N0170
    Indole-3-carbinol
    15+ Cited Publications

    Indole-3-methanol

    		 NF-κB Aryl Hydrocarbon Receptor E1/E2/E3 Enzyme Endogenous Metabolite Cancer
    Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
    Indole-3-carbinol
  • HY-19776
    3α-Aminocholestane
    5+ Cited Publications

    		 Phosphatase Cancer
    3α-Aminocholestane is a selective SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) inhibitor with an IC50 of ~2.5 μM.
    3α-Aminocholestane
  • HY-10990
    Abexinostat
    5+ Cited Publications

    CRA 024781; PCI-24781

    		 HDAC Cancer
    Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM. Abexinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
    Abexinostat
  • HY-13322
    Pracinostat
    5+ Cited Publications

    SB939

    		 Beta-lactamase HDAC Apoptosis Cancer
    Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
    Pracinostat
  • HY-13271
    Tubastatin A Hydrochloride
    35+ Cited Publications

    Tubastatin A HCl; TSA HCl

    		 Beta-lactamase HDAC Autophagy Apoptosis Cancer
    Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubastatin A Hydrochloride
  • HY-164607
    YL-5092

    		DNA/RNA Synthesis Apoptosis Cancer
    YL-5092 is a selective YT521-B homology (YTH) domain-containing protein 1 (YTHDC1) inhibitor with an IC50 of 7.4 nM and a KD of 29.6 nM. YL-5092 can suppress cancer cell proliferation and induce cell G0/G1 phase arrest and apoptosis. YL-5092 can be used for the research of cancer, such as acute myeloid leukemia (AML) .
    YL-5092
  • HY-139782
    SKLB325
    2 Publications Verification

    		 Histone Demethylase Apoptosis Cancer
    SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis . SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .
    SKLB325
  • HY-15191
    Sabutoclax
    1 Publications Verification

    BI-97C1

    		 Bcl-2 Family Cancer
    Sabutoclax is a potent and effective Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1) inhibitor with IC50s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively. Sabutoclax increases Bax, Bim, PUMA and survivin expression .
    Sabutoclax
  • HY-154919
    DC-Y13-27
    4 Publications Verification

    		 YTHDF FOXO MMP Pyroptosis Interleukin Related Endocrinology Cancer
    DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .
    DC-Y13-27
  • HY-19328
    ACY-775
    2 Publications Verification

    		 HDAC Cardiovascular Disease Neurological Disease
    ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM . ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
    ACY-775
  • HY-W017132
    2,4-PDCA

    		MOFs Histone Demethylase Cancer
    2,4-PDCA (2,4 pyridine dicarboxylic acid) is a broad-spectrum inhibitor of 2OG oxygenase, including JmjC domain-containing family of histone demethylases (JHDMs). 2,4-PDCA is a target chemical in the field of bio-based plastics .
    2,4-PDCA
  • HY-124418
    SBI-477
    1 Publications Verification

    		 Fluorescent Dye Insulin Receptor LXR Arrestin Metabolic Disease
    SBI-477 is a chemical probe that stimulates insulin signaling by deactivating the transcription factor MondoA. SBI-477 can lead to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes .
    SBI-477
  • HY-135299
    CH6953755
    5 Publications Verification

    		 Src Cancer
    CH6953755 is a potent, orally active and selective YES1 kinase (a member of the SRC family) inhibitor with an IC50 of 1.8 nM. CH6953755 inhibits YES1 kinase, leading to antitumor activity against YES1 Gene -amplified cancers in vitro and in vivo .
    CH6953755
  • HY-174982
    YTHDF2 ligand-1

    		YTHDF Cancer
    YTHDF2 ligand-1 (Compound 23) is a competitive, selective, and high-affinity YTHDF2 ligand with an IC50 of 11 μM and a Kd of 1.3 μM. YTHDF2 ligand-1 competes with m 6A-RNA for binding to YTHDF2. YTHDF2 ligand-1 is applicable for cancer research .
    YTHDF2 ligand-1
  • HY-18685
    CPDA

    		Phosphatase Metabolic Disease
    CPDA is a novel potent SH2 domain-containing inositol phosphatase 2 (SHIP2) inhibitor.
    CPDA
  • HY-122198
    ML367
    1 Publications Verification

    		 Checkpoint Kinase (Chk) Cancer
    ML367 is a potent inhibitor of ATPase family AAA domain-containing protein 5 (ATAD5) stabilization, acts as a probe molecule that has low micromolar inhibitory activity. ML367 blocks DNA repair pathways, suppresses general DNA damage responses including RPA32-phosphorylation and CHK1-phosphorylation in response to UV irradiation .
    ML367
  • HY-176848
    SKLB-Y13

    		YTHDF Apoptosis MMP Caspase Cancer
    SKLB-Y13 is a selective YTHDF1 inhibitor with an IC50 of 0.76 μM and a KD of 5.097 μM. SKLB-Y13 binds to the Tyr397 and Trp470 residues in the m 6A-binding pocket of YTHDF1, disrupting the interaction between YTHDF1 and m 6A-modified mRNA. SKLB-Y13 inhibits cancer cell proliferation and promotes apoptosis. SKLB-Y13 is applicable to breast cancer-related research .
    SKLB-Y13
  • HY-100624
    Ryuvidine

    		CDK DNA/RNA Synthesis Histone Demethylase Histone Methyltransferase Inflammation/Immunology Cancer
    Ryuvidine is a potent inhibitor of SET domain-containing protein 8(SETD8) with an IC50 of 0.5 µM and suppresses monomethylation of H4K20. Ryuvidine also inhibits CDK4 with an IC50 of 6.0 μM. Ryuvidine also inhibits KDM5A and blocks DNA synthesis. Ryuvidine has anticancer activity against tumors such as breast cancer. Ryuvidine improves arthritis .
    Ryuvidine
  • HY-125859B
    Lactoperoxidase, bovine milk

    		Bacterial Infection
    Lactoperoxidase, bovine milk is an antimicrobial protein that belongs to the mammalian heme peroxidase family. Lactoperoxidase, bovine milk uses H2O2 to catalyze the oxidation of its preferred halide substrates including I −, Br −, F −, or the pseudohalide SCN − .
    Lactoperoxidase, bovine milk
  • HY-152670
    JC2-11
    1 Publications Verification

    		 NOD-like Receptor (NLR) AIM2 Inflammation/Immunology
    JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1 .
    JC2-11
  • HY-168610
    YTH-IN-1

    		Epigenetic Reader Domain YTHDF Cancer
    YTH-IN-1 (compound N-7) is a pan-YTH domain inhibitor with the IC50 values of 39 μM, 34 μM, 35 μM, 48 μM and 30 μM for human YTH YTHDF1, YTH YTHDF2, YTH YTHDF3, YTH YTHDC1, and YTH YTHDC2, respectively .
    YTH-IN-1
  • HY-129121
    ML-​226

    		MAGL Neurological Disease
    ML226 is a potent α/β hydrolase domain-containing protein 11 (ABHD11) inhibitor in vitro and in situ with IC50s of 15 and 0.68 nM, respectively .
    ML-​226
  • HY-173008
    YTHDF2-IN-1

    		Apoptosis YTHDF Cancer
    YTHDF2-IN-1 (Compound CK-75) is a selective YTHDF2 inhibitor (Kd = 26.2 μM). YTHDF2-IN-1 binds to a small hydrophobic pocket on the YTH domain of YTHDF2, disrupting the interaction between YTHDF2 and m 6A-modified RNA. YTHDF2-IN-1 induces cell cycle arrest and Apoptosis. YTHDF2-IN-1 is applicable to research on chronic myeloid leukemia, colon cancer and choriocarcinoma .
    YTHDF2-IN-1
  • HY-157251
    UNC8153 TFA

    		Histone Methyltransferase Cancer
    UNC8153 TFA is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 TFA reduces the cellular levels of both NSD2 protein (DC50 in cell U2OS is 0.35 μM) and the H3K36me2 chromatin mark. UNC8153 TFA contains a simple warhead that confers proteasome-dependent degradation of NSD2 .
    UNC8153 TFA
  • HY-161574
    LLC0424

    		PROTACs Histone Methyltransferase Cancer
    LLC0424 is a potent and selective cereblon-based PROTAC nuclear receptor-binding SET domain-containing 2 (NSD2) degrader. LLC0424 effectively degraded NSD2 with a DC50 of 20 nM in RPMI-8402 cells. LLC0424 selectively induces NSD2 degradation in a cereblon- and proteasome-dependent fashion. (Blue: CRBN ligand (HY-14658), Black: linker (HY-40002); Pink: NSD2 inhibitor (HY-161575)) .
    LLC0424
  • HY-100871
    WT-161
    5+ Cited Publications

    		 Beta-lactamase HDAC Apoptosis Cancer
    WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
    WT-161
  • HY-N0086R
    N6-Methyladenosine (Standard)
    1 Publications Verification

    6-Methyladenosine (Standard); N-Methyladenosine (Standard)

    		 Endogenous Metabolite Influenza Virus Reference Standards Infection
    N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .
    N6-Methyladenosine (Standard)
  • HY-N4081
    Dracorhodin
    1 Publications Verification

    		 Others Cardiovascular Disease
    Dracorhodin, the main component in sanguis draconis, is a flavylium compound belonging to the anthocyanin family. Dracorhodin can induce vasodilatation .
    Dracorhodin
  • HY-148187
    NLRP3-IN-11

    		NOD-like Receptor (NLR) Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases .
    NLRP3-IN-11
  • HY-111952
    SR-4995

    CID 16016685

    		 Endogenous Metabolite Others
    SR-4995 (CID 16016685) is a highly effective and selective ligand for α-β-hydrolase domain-containing 5 (ABHD5), facilitating the activation of adipose triglyceride lipase (ATGL) by displacing ABHD5 from its inhibitory regulators, perilipin-1 (PLIN1) and PLIN5. It directly interacts with ABHD5, inhibiting its association with PLIN1, and promotes lipolysis in adipocytes and muscle tissues while circumventing PKA-dependent signaling pathways.
    SR-4995
  • HY-155938
    Cyano-myracrylamide
    1 Publications Verification

    		 Acyltransferase Neurological Disease Inflammation/Immunology Cancer
    Cyano-myracrylamide is an inhibitor of zinc finger DHHC domain-containing palmitoyltransferase 20 (zDHHC20) with an IC50 value of 1.35 µM. Cyano-myracrylamide also inhibits the S-Acylation of EGFR and CD36. Cyano-myracrylamide also inhibits S-acylation of Legionella E3 ligase GobX, MyD88, and Ras, which are substrates of zDHHC20, zDHHC9, and zDHHC6, respectively, in HEK293T cells expressing recombinant Legionella GobX, recombinant human MyD88, or endogenous Ras .
    Cyano-myracrylamide
  • HY-108486
    Herbimycin A

    		Bacterial Antibiotic Infection
    Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 v-src and p210 BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.
    Herbimycin A
  • HY-RS15939
    YTHDF3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) YTHDF Others

    YTHDF3 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    YTHDF3 Human Pre-designed siRNA Set A
    YTHDF3 Human Pre-designed siRNA Set A
  • HY-161727
    P2Y14R antagonist 1

    		P2Y Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis .
    P2Y14R antagonist 1
  • HY-N0170R
    Indole-3-carbinol (Standard)

    Indole-3-methanol (Standard)

    		 NF-κB Aryl Hydrocarbon Receptor E1/E2/E3 Enzyme Endogenous Metabolite Reference Standards Cancer
    Indole-3-carbinol (Standard) is the analytical standard of Indole-3-carbinol. This product is intended for research and analytical applications. Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
    Indole-3-carbinol (Standard)
  • HY-111953
    SR-4559

    		MAGL ATGL Metabolic Disease
    SR-4559 is a α/β hydrolase domain-containing protein 5 (ABHD5) ligand. SR-4559 activates adipose triglyceride lipase (ATGL) and stimulates lipolysis by inhibiting ABHD5-PLIN interactions in adipocytes and muscle cells. SR-4559 can be used for metabolic diseases like Chanarin Dorfman syndrome research .
    SR-4559
  • HY-157251A
    UNC8153

    		Histone Methyltransferase Cancer
    UNC8153 is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 reduces the cellular levels of both NSD2 protein (DC50 in cell U2OS is 0.35 μM) and the H3K36me2 chromatin mark. UNC8153 contains a simple warhead that confers proteasome-dependent degradation of NSD2 .
    UNC8153
  • HY-168929
    SHP1 activator 1

    		SHP1 Fluorescent Dye Phosphatase STAT Apoptosis Cancer
    SHP1 activator 1 (Compound 3n) is an activator for src homology-2 domain-containing protein tyrosine phosphatase 1(SHP1) with an EC50 of 17.66 μM. SHP1 activator 1 inhibits the proliferation of ABC-DLBCL cells, induces apoptosis by inhibiting STAT3 signaling pathway. SHP1 activator 1 emitts blue and green fluorescence signalis in MDA-MB-231 cell, and can be used as a cell imaging agent .
    SHP1 activator 1
  • HY-P990021
    Calpurbatug

    TRL1068

    		 Bacterial Others
    Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
    Calpurbatug
  • HY-117395
    PU-H54

    		HSP Cancer
    PU-H54, a Grp94-selective inhibitor, can be used for the research of breast cancer. Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy . PU-H54 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PU-H54
  • HY-119254A
    trans-BAY-850

    		Epigenetic Reader Domain Metabolic Disease
    trans-BAY-850 is the trans isomer of BAY-850 (HY-119254). BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC50 of 166 nM.
    trans-BAY-850
  • HY-126031A
    (S)-KT109

    		Endogenous Metabolite Others
    (S)-KT109 is an inhibitor of diacylglycerol lipase β (DAGLβ) with low inhibitory activity (IC50 = 39.81 nM). (S)-KT109 has relatively low inhibitory activity against DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol (IC50 = 794.3 nM). (S)-KT109 also has relatively low inhibitory activity against α/β-amidase domain-containing 6 (ABHD6) (IC50 = 630.9 nM) .
    (S)-KT109
  • HY-162470
    DBPR728

    		Aurora Kinase Cancer
    DBPR728 is an acyl prodrug of 6K465 that carries fewer hydrogen bond donors. 6K465 acts as an Aurora kinase inhibitor that destabilizes MYC family cancer proteins and has antitumor efficacy. DBPR728 has the potential to inhibit cancers that overexpress C-MYC and N-MYC, with a 10-fold increase in oral bioavailability compared to 6K465 .
    DBPR728
  • HY-RS15937
    YTHDF1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) YTHDF Others

    YTHDF1 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    YTHDF1 Human Pre-designed siRNA Set A
    YTHDF1 Human Pre-designed siRNA Set A
  • HY-RS15938
    YTHDF2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) YTHDF Others

    YTHDF2 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    YTHDF2 Human Pre-designed siRNA Set A
    YTHDF2 Human Pre-designed siRNA Set A
  • HY-RS17237
    Ythdf1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ythdf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ythdf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ythdf1 Mouse Pre-designed siRNA Set A
    Ythdf1 Mouse Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: